2016 Pharmaceutical and Biopharmaceutical M&A Scorecard
Merger and acquisition activity is constantly shaping and reshaping the pharmaceutical and biopharmaceutical industries. While 2016 did not go as expected from an M&A perspective what didn’t happen was every bit as important as what did happen.
The 2016 Pharmaceutical & Biopharmaceutical Scorecard includes:
- What happened and what was expected to happen?
- Recap of key movements in 2016
- Detailed scorecard of 2016 M&A activity
- What’s on the horizon for 2017?